Canada markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1700-0.0300 (-1.36%)
At close: 04:00PM EDT
2.1900 +0.02 (+0.92%)
After hours: 07:30PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 553.21M
Enterprise Value 70.16M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)4.19k
Price/Book (mrq)0.84
Enterprise Value/Revenue 539.67
Enterprise Value/EBITDA -0.31

Trading Information

Stock Price History

Beta (5Y Monthly) -0.56
52-Week Change 31.40%
S&P500 52-Week Change 322.36%
52 Week High 33.9700
52 Week Low 31.3200
50-Day Moving Average 32.3220
200-Day Moving Average 32.0944

Share Statistics

Avg Vol (3 month) 3909.35k
Avg Vol (10 day) 3965.74k
Shares Outstanding 5254.94M
Implied Shares Outstanding 6254.94M
Float 8163.65M
% Held by Insiders 115.54%
% Held by Institutions 172.68%
Shares Short (Apr 15, 2024) 418.23M
Short Ratio (Apr 15, 2024) 418.38
Short % of Float (Apr 15, 2024) 410.17%
Short % of Shares Outstanding (Apr 15, 2024) 47.15%
Shares Short (prior month Mar 15, 2024) 410.38M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-454,392.33%

Management Effectiveness

Return on Assets (ttm)-18.18%
Return on Equity (ttm)-31.53%

Income Statement

Revenue (ttm)130k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)-100.00%
Gross Profit (ttm)N/A
EBITDA -225.25M
Net Income Avi to Common (ttm)-234.63M
Diluted EPS (ttm)-0.9300
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)546.22M
Total Cash Per Share (mrq)2.15
Total Debt (mrq)63.17M
Total Debt/Equity (mrq)9.65%
Current Ratio (mrq)16.07
Book Value Per Share (mrq)2.58

Cash Flow Statement

Operating Cash Flow (ttm)-163.69M
Levered Free Cash Flow (ttm)-90.36M